The FDA has issued a warning that a counterfeit version of the anti-cancer drug Avastin is being distributed to clinics in the U.S. According to drug maker Roche, counterfeit Avastin does not contain bevacizumab, the active ingredient in the drug. In a written statement from Genentech (part of the Roche family), the company cited the fake version as unsafe and ineffective.
According to reports, the FDA has contacted 19 clinics in the U.S. that were known to have purchased counterfeit Avastin from an overseas supplier. The investigation could reveal more clinics in the future.
More information for health care providers and patients can be found in this press release from Genentech.